Study summary
A second IGF-1R antibody reduced eye bulging in 70% of patients after five infusions
70%proptosis responders at week 15, vs 5% with placebo
What was tested
Veligrotug, an antibody that blocks the IGF-1 receptor driving tissue swelling behind the eyes, given as 5 infusions over 12 weeks, against placebo, for active thyroid eye disease.
What they found
- Eye bulging (proptosis) improved by 2 mm or more in 70% vs 5%.
- Double vision resolved in 49% vs 12%.
- Improvements started by week 3; 70% of responders kept their response at week 52.
What it means
A shorter course than teprotumumab, approved for both active and chronic disease.
Last reviewed 2026-11-15 by the Find a Trial editorial team.
Information on this page is for educational purposes and is not medical advice.
Always consult qualified healthcare professionals about clinical trial participation.